Marksans Pharma (MARKSANS) Resumen de Acciones
Marksans Pharma Limited, junto con sus filiales, se dedica a la investigación, fabricación, comercialización y venta de formulaciones farmacéuticas en Estados Unidos, Norteamérica, Europa, Reino Unido, Australia, Nueva Zelanda y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 2/6 |
| Salud financiera | 6/6 |
| Dividendos | 4/6 |
Recompensas
Análisis de riesgos
MARKSANS Community Fair Values
Create NarrativeSee what 32 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Marksans Pharma Limited
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | ₹259.70 |
| Máximo en las últimas 52 semanas | ₹278.80 |
| Mínimo de 52 semanas | ₹155.00 |
| Beta | 1.09 |
| Cambio en 1 mes | 11.37% |
| Variación en 3 meses | 52.76% |
| Cambio de 1 año | 0.89% |
| Variación en 3 años | 184.29% |
| Variación en 5 años | 195.11% |
| Variación desde la OPV | 854.96% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 23
MARKSANS: Dividend Decision And Stable Assumptions Will Shape Measured Future Share Rerating
Analysts have kept their Marksans Pharma fair value estimate broadly unchanged at ₹266. This reflects consistent assumptions on discount rate, revenue growth, profit margin, and future P/E in their latest price target update.
Nueva narrativa • Jun 15
Unused Capacity And Regulated Market Expansion Will Drive A Stronger Future Margin Profile
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceuticals company focused on generic formulations across regulated markets including the U.S., U.K., Europe, Australia, New Zealand and select other regions. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Jun 04
MARKSANS: Upcoming Dividend Decision Will Support Positive Share Price Rerating
Analysts have lifted the Marksans Pharma price target from ₹216.67 to ₹266.00, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and an adjusted future P/E input. What's in the News A board meeting was held on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Recent updates
Actualización de narrativa • Jun 23
MARKSANS: Dividend Decision And Stable Assumptions Will Shape Measured Future Share Rerating
Analysts have kept their Marksans Pharma fair value estimate broadly unchanged at ₹266. This reflects consistent assumptions on discount rate, revenue growth, profit margin, and future P/E in their latest price target update.Nueva narrativa • Jun 15
Unused Capacity And Regulated Market Expansion Will Drive A Stronger Future Margin Profile
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceuticals company focused on generic formulations across regulated markets including the U.S., U.K., Europe, Australia, New Zealand and select other regions. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Jun 04
MARKSANS: Upcoming Dividend Decision Will Support Positive Share Price Rerating
Analysts have lifted the Marksans Pharma price target from ₹216.67 to ₹266.00, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and an adjusted future P/E input. What's in the News A board meeting was held on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Nueva narrativa • Jun 01
Rising North America Dependence And Overextended Pipeline Will Pressure Margins And Earnings
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceutical company focused on generic formulations across regulated markets including North America, the U.K., Europe, Australia and New Zealand. What are the underlying business or industry changes driving this perspective?Artículo de análisis • May 29
Earnings Beat: Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Marksans Pharma Limited ( NSE:MARKSANS ) defied analyst predictions to release its full-year results, which were ahead...Artículo de análisis • May 28
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Artículo de análisis • Feb 10
Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Artículo de análisis • Jan 15
Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...Artículo de análisis • Dec 09
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Nov 17
Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Actualización de narrativa • Nov 11
MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum
Analysts have reduced their price target for Marksans Pharma from ₹231.67 to ₹216.67. They cite slight increases in the discount rate and a modest drop in the company's projected future price-to-earnings ratio as reasons for the adjustment.Artículo de análisis • Oct 15
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Actualización de narrativa • Aug 15
Developed Markets Will Support Affordable Generic Expansion
Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67. What's in the News Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.Artículo de análisis • Aug 15
Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Artículo de análisis • Aug 07
Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Artículo de análisis • Jun 28
Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Marksans Pharma fair value estimate is ₹239 With ₹253 share...Artículo de análisis • May 27
We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings
Marksans Pharma Limited's ( NSE:MARKSANS ) robust recent earnings didn't do much to move the stock. However the...Artículo de análisis • May 22
₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Artículo de análisis • May 14
Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Artículo de análisis • Mar 23
Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Mar 05
Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 24.6x...Artículo de análisis • Feb 15
Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...Artículo de análisis • Feb 01
Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Marksans Pharma's estimated fair value is ₹190 based on 2 Stage Free Cash Flow to Equity Marksans Pharma's...
Nueva narrativa • Jan 28
Teva Pharma Facility And US Expansion To Strengthen Future Outlook
Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.Artículo de análisis • Nov 27
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Marksans Pharma Limited ( NSE:MARKSANS ) shares have been powering on, with a gain of...Artículo de análisis • Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Artículo de análisis • Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Marksans Pharma Limited ( NSE:MARKSANS ) shares have continued their recent momentum with a 45% gain in the last month...Artículo de análisis • Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Marksans Pharma Limited ( NSE:MARKSANS ) shareholders would be excited to see that the share price has had a great...Artículo de análisis • Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
The market shrugged off Marksans Pharma Limited's ( NSE:MARKSANS ) solid earnings report. We did some digging and...Artículo de análisis • May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Artículo de análisis • Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider...Artículo de análisis • Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Artículo de análisis • Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Rentabilidad de los accionistas
| MARKSANS | IN Pharmaceuticals | Mercado IN | |
|---|---|---|---|
| 7D | -1.4% | 3.3% | 1.0% |
| 1Y | 0.9% | 12.6% | -1.4% |
Rentabilidad vs. Industria: Los resultados de MARKSANS fueron inferiores a los de la industria Indian Pharmaceuticals, que obtuvo un rendimiento del 12.6% el año pasado.
Rentabilidad vs. Mercado: MARKSANS superó al mercado Indian, que obtuvo un rendimiento del -1.4% el año pasado.
Volatilidad de los precios
| MARKSANS volatility | |
|---|---|
| MARKSANS Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.1% |
Precio estable de las acciones: MARKSANS no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Indian.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MARKSANS (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1992 | 1,840 | Mark Saldanha | marksanspharma.com |
Marksans Pharma Limited, junto con sus filiales, se dedica a la investigación, fabricación, comercialización y venta de formulaciones farmacéuticas en Estados Unidos, Norteamérica, Europa, Reino Unido, Australia, Nueva Zelanda y a escala internacional. La empresa ofrece productos en las áreas terapéuticas de tratamiento del dolor, vías respiratorias altas, cardiovascular, sistema nervioso central, antidiabético, gastrointestinal, analgésicos, vías respiratorias altas, cuidado del oído, cuidado de la piel, anticanceroso, antiulceroso, antialérgico, antivírico, dietético, cardiaco, dermatológico, antihistamínico, antifúngico, antivírico, laxante, y resfriado y tos. También produce una gama de formas sólidas de dosificación oral, incluidos comprimidos y cápsulas de gelatina dura; geles blandos; aceites esenciales; ungüentos; y cremas y líquidos, así como medicamentos con receta.
Resumen de fundamentos de Marksans Pharma Limited
| Estadísticas fundamentales de MARKSANS | |
|---|---|
| Capitalización bursátil | ₹119.84b |
| Beneficios(TTM) | ₹4.18b |
| Ingresos (TTM) | ₹29.51b |
28.2x
Ratio precio-beneficio (PE)4.0x
Ratio precio-ventas (PS)¿Está MARKSANS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MARKSANS | |
|---|---|
| Ingresos | ₹29.51b |
| Coste de los ingresos | ₹12.77b |
| Beneficio bruto | ₹16.74b |
| Otros gastos | ₹12.56b |
| Beneficios | ₹4.18b |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 9.22 |
| Margen bruto | 56.72% |
| Margen de beneficio neto | 14.16% |
| Ratio deuda/patrimonio | 1.0% |
¿Cómo se ha desempeñado MARKSANS a largo plazo?
Ver rendimiento histórico y comparativaDividendos
0.3%
Rentabilidad actual por dividendo10%
Ratio de pagos¿Paga MARKSANS dividendos fiables?
Ver historial de dividendos e índices de referencia de MARKSANS| fechas de dividendos de Marksans Pharma | |
|---|---|
| Fecha ex dividendo | Aug 20 2026 |
| Fecha de pago de dividendos | Sep 26 2026 |
| Días hasta ex dividendo | 44 days |
| Días hasta la fecha de pago de dividendos | 81 days |
¿Paga MARKSANS dividendos fiables?
Ver historial de dividendos e índices de referencia de MARKSANSAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/06 13:29 |
| Precio de las acciones al final del día | 2026/07/06 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Marksans Pharma Limited está cubierta por 4 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Maitri Sheth | Choice Equity Broking Private Limited |
| Nitin Agarwal | DAM Capital Advisors |